PVLA
Price:
$93.8
Market Cap:
$1.11B
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Industry
Biotechnology
IPO Date
2015-01-02
Stock Exchange
NASDAQ
Ticker
PVLA
According to Palvella Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -32.01. This represents a change of 421.40% compared to the average of -6.14 of the last 4 quarters.
The mean historical PE Ratio of Palvella Therapeutics, Inc. over the last ten years is -0.29. The current -32.01 PE Ratio has changed 1.09% with respect to the historical average. Over the past ten years (40 quarters), PVLA's PE Ratio was at its highest in in the June 2023 quarter at 1.17. The PE Ratio was at its lowest in in the September 2025 quarter at -15.28.
Average
-0.29
Median
-0.31
Minimum
-1.53
Maximum
1.15
Discovering the peaks and valleys of Palvella Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 58.49%
Maximum Annual PE Ratio = 1.15
Minimum Annual Increase = -342.65%
Minimum Annual PE Ratio = -1.53
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.53 | -232.85% |
| 2023 | 1.15 | -342.65% |
| 2022 | -0.48 | 58.49% |
| 2021 | -0.30 | -3.56% |
The current PE Ratio of Palvella Therapeutics, Inc. (PVLA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.28
5-year avg
-0.29
10-year avg
-0.29
Palvella Therapeutics, Inc.’s PE Ratio is less than GH Research PLC (-23.21), less than ARS Pharmaceuticals, Inc. (-12.31), less than Nanobiotix S.A. (-12.92), less than ProKidney Corp. (-4.64), less than Savara Inc. (-12.50), less than Kura Oncology, Inc. (-4.84), less than Arbutus Biopharma Corporation (-20.00), less than Rezolute, Inc. (-13.00), less than EyePoint Pharmaceuticals, Inc. (-5.70), less than Tyra Biosciences, Inc. (-12.44),
| Company | PE Ratio | Market cap |
|---|---|---|
| -23.21 | $952.15M | |
| -12.31 | $978.98M | |
| -12.92 | $1.04B | |
| -4.64 | $723.22M | |
| -12.50 | $1.30B | |
| -4.84 | $1.04B | |
| -20.00 | $847.53M | |
| -13.00 | $899.46M | |
| -5.70 | $1.15B | |
| -12.44 | $1.18B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Palvella Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Palvella Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Palvella Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Palvella Therapeutics, Inc. (PVLA)?
What is the highest PE Ratio for Palvella Therapeutics, Inc. (PVLA)?
What is the 3-year average PE Ratio for Palvella Therapeutics, Inc. (PVLA)?
What is the 5-year average PE Ratio for Palvella Therapeutics, Inc. (PVLA)?
How does the current PE Ratio for Palvella Therapeutics, Inc. (PVLA) compare to its historical average?